This week’s ARCS Biopharma & Medtech Wrap dives into the biggest headlines shaping the life sciences sector – from pharma restructures and drug pricing debates to medtech innovation and Australian biotech success stories.
We cover:
Pharma: Novo Nordisk’s 9,000 job cuts, Lundbeck’s global exits, Takeda’s narcolepsy breakthrough, and the growing debate on PBS and international drug pricing.
Medtech: A $160m investment in robotics and AI in Sydney, plus Professor Edward Holmes’ award-winning AI and genomics research.
Biotech & Investment: Cartherics and HaemaLogiX shine at the Asia Pacific Cell & Gene Awards, while local biotechs secure funding and approvals.
People Movement: Leadership changes at Novartis and BeOne, and Daiichi Sankyo’s recognition as a top employer.
We’ll unpack what it means for you – from clinicians and researchers to policy specialists and industry leaders. Plus, we connect the dots to upcoming ARCS events: the Leadership & Communication Symposium (18 Sept, Sydney) and the Global Cell & Gene Summit (25 Feb 2026, Sydney).
🎧 Tune in for insights, context, and commentary on the news that matters to Australia’s life sciences community.
👉 Join the conversation. Join ARCS today: arcs.com.au
